THERANEXUS: MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPOSING THE SHARE CAPITAL – 02/10/2022 at 6:40 p.m.


Lyon, February 10, 2022

– Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, publishes the number of shares making up its capital and the total number of voting rights (articles L. 233-8 II of the Commercial Code and 223-16 of the AMF General Regulations) as of January 31, 2022.

Dated

Number of shares making up the share capital

Total number of theoretical voting rights*

January 31, 2022

5,142,114

6,210,407

* Theoretical voting rights are calculated in accordance with Article 223-11 of the General Regulations of the AMF (Financial Markets Authority), on the basis of all the shares to which voting rights are attached, including shares without voting rights.

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company spun off from the CEA that develops drug candidates for the treatment of diseases of the nervous system.

Thanks to its knowledge of neuro-glial interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of clinical-stage active ingredients. This repositioned drug combination strategy based on a solid commercial case and with a real ability to quickly demonstrate their clinical value allows the company to generate various proprietary drug candidates with high added value, to significantly reduce the time and costs of development and considerably increase the chances of market access for its drugs.

To this end, THERANEXUS is positioned in several indications, including Parkinson’s disease and Batten’s disease, for which no treatment is currently available on the market.

THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259-ALTHX).

www.theranexus.com

More information on:

http://www.theranexus.com

Click and follow us on Twitter and Linkedln

contacts

THERANEXUS

Thierry LAMBERT

Financial and Administrative Director

[email protected]

NEWCAP

Théo MARTIN/Pierre LAURENT


Investor Relations

+33 (0)1 44 71 94 97

[email protected]

FP2COM

Florence PORTEJOIE


Media relations

+ 33 (0)6 07 76 82 83

[email protected]


This publication has the service “? Actusnews SECURITY MASTER”.


– SECURITY MASTER Key:

lG2cYsablG/Jy5+fk52ZaWpnb5pkmmmXapbKlZZsmMeWaGlol2hlaZfGZnBkl2Vu

– To check this key:

https://www.security-master-key.com.



Regulated information:


Total number of voting rights and capital:

– Information relating to the total number of voting rights and shares making up the capital


Full and original press release in PDF format:

https://www.actusnews.com/news/73208-theranexus_cp_ddv-31012022.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86